Three doses of Diphtheria, Tetanus and Pertussis (DTP3)
Three doses of Diphtheria Toxoid, Tetanus Toxoid and Pertussis vaccine is needed for full protection . Used by GAVI as a surrogate measure of immunization program strength. One of GAVIís goals is for all countries to achieve routine immunization coverage (DTP3) at 90% nationally with at least 80% coverage in every district by 2010.
Diphtheria, Tetanus and Acellular Pertussis vaccine (DTaP)
Diphtheria, Tetanus and Acellular Pertussis vaccine (DTaP), was introduced in 1997 to meet the regulatory requirements of the developed countries. DTaP is a newer vaccine which is more expensive than the older DTwP.
Diphtheria, Tetanus, whole cell Pertussis Vaccine (DTwP)
Diphtheria, Tetanus, whole cell Pertussis Vaccine (DTwP), is still used in most developing countries (and GAVI) as part of routine immunization.
Data Quality Audit (DQA)
In order to receive the reward element of GAVIís immunization services support (ISS), countries must demonstrate an increase in the number of additional infants immunized compared to the previous year, and have passed a data quality audit.
The DQA was created by GAVI as a means to verify countriesí reported immunization coverage as well as to enhance immunization monitoring and reporting systems.
Data Quality Self Assessment (DQS)
Tool that enables countries to assess their own routine reporting systems in advance of external data quality audits.
Developing Country Vaccine Manufacturers Network (DCVMN)
The DCVMN is an affinity group of vaccine producers from developing and middle income countries globally, interested in networking and collaboration amongst themselves.